Cargando…

Application of triple evaluation method in predicting the efficacy of neoadjuvant therapy for breast cancer

OBJECTIVE: To analyze the factors related to the efficacy of neoadjuvant therapy for breast cancer and find appropriate evaluation methods for evaluating the efficacy of neoadjuvant therapy METHODS: A total of 143 patients with breast cancer treated by neoadjuvant chemotherapy at Baotou Cancer Hospi...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Xu, Li, Hui, Dong, Sha-Sha, Zhou, Shui-Ying, Wang, Cai-Hong, Guo, Lin, Yang, Jie, Zhang, Gang-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052864/
https://www.ncbi.nlm.nih.gov/pubmed/36978164
http://dx.doi.org/10.1186/s12957-023-02998-8
_version_ 1785015256033001472
author Han, Xu
Li, Hui
Dong, Sha-Sha
Zhou, Shui-Ying
Wang, Cai-Hong
Guo, Lin
Yang, Jie
Zhang, Gang-Ling
author_facet Han, Xu
Li, Hui
Dong, Sha-Sha
Zhou, Shui-Ying
Wang, Cai-Hong
Guo, Lin
Yang, Jie
Zhang, Gang-Ling
author_sort Han, Xu
collection PubMed
description OBJECTIVE: To analyze the factors related to the efficacy of neoadjuvant therapy for breast cancer and find appropriate evaluation methods for evaluating the efficacy of neoadjuvant therapy METHODS: A total of 143 patients with breast cancer treated by neoadjuvant chemotherapy at Baotou Cancer Hospital were retrospectively analyzed. The chemotherapy regimen was mainly paclitaxel combined with carboplatin for 1 week, docetaxel combined with carboplatin for 3 weeks, and was replaced with epirubicin combined with cyclophosphamide after evaluation of disease progression. All HER2-positive patients were treated with simultaneous targeted therapy, including trastuzumab single-target therapy and trastuzumab combined with pertuzumab double-target therapy. Combined with physical examination, color Doppler ultrasound, and magnetic resonance imaging (MRI), a systematic evaluation system was initially established—the “triple evaluation method.” A baseline evaluation was conducted before treatment. The efficacy was evaluated by physical examination and color Doppler every cycle, and the efficacy was evaluated by physical examination, color Doppler, and MRI every two cycles. RESULTS: The increase in ultrasonic blood flow after treatment could affect the efficacy of monitoring. The presence of two preoperative time–signal intensity curves is a therapeutically effective protective factor for inflow. The triple evaluation determined by physical examination, color Doppler ultrasound, and MRI in determining clinical efficacy is consistent with the effectiveness of the pathological gold standard. CONCLUSION: The therapeutic effect of neoadjuvant therapy can be better evaluated by combining clinical physical examination, color ultrasound, and nuclear magnetic resonance evaluation. The three methods complement each other to avoid the insufficient evaluation of a single method, which is convenient for most prefecty-level hospitals. Additionally, this method is simple, feasible, and suitable for promotion.
format Online
Article
Text
id pubmed-10052864
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100528642023-03-30 Application of triple evaluation method in predicting the efficacy of neoadjuvant therapy for breast cancer Han, Xu Li, Hui Dong, Sha-Sha Zhou, Shui-Ying Wang, Cai-Hong Guo, Lin Yang, Jie Zhang, Gang-Ling World J Surg Oncol Research OBJECTIVE: To analyze the factors related to the efficacy of neoadjuvant therapy for breast cancer and find appropriate evaluation methods for evaluating the efficacy of neoadjuvant therapy METHODS: A total of 143 patients with breast cancer treated by neoadjuvant chemotherapy at Baotou Cancer Hospital were retrospectively analyzed. The chemotherapy regimen was mainly paclitaxel combined with carboplatin for 1 week, docetaxel combined with carboplatin for 3 weeks, and was replaced with epirubicin combined with cyclophosphamide after evaluation of disease progression. All HER2-positive patients were treated with simultaneous targeted therapy, including trastuzumab single-target therapy and trastuzumab combined with pertuzumab double-target therapy. Combined with physical examination, color Doppler ultrasound, and magnetic resonance imaging (MRI), a systematic evaluation system was initially established—the “triple evaluation method.” A baseline evaluation was conducted before treatment. The efficacy was evaluated by physical examination and color Doppler every cycle, and the efficacy was evaluated by physical examination, color Doppler, and MRI every two cycles. RESULTS: The increase in ultrasonic blood flow after treatment could affect the efficacy of monitoring. The presence of two preoperative time–signal intensity curves is a therapeutically effective protective factor for inflow. The triple evaluation determined by physical examination, color Doppler ultrasound, and MRI in determining clinical efficacy is consistent with the effectiveness of the pathological gold standard. CONCLUSION: The therapeutic effect of neoadjuvant therapy can be better evaluated by combining clinical physical examination, color ultrasound, and nuclear magnetic resonance evaluation. The three methods complement each other to avoid the insufficient evaluation of a single method, which is convenient for most prefecty-level hospitals. Additionally, this method is simple, feasible, and suitable for promotion. BioMed Central 2023-03-29 /pmc/articles/PMC10052864/ /pubmed/36978164 http://dx.doi.org/10.1186/s12957-023-02998-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Han, Xu
Li, Hui
Dong, Sha-Sha
Zhou, Shui-Ying
Wang, Cai-Hong
Guo, Lin
Yang, Jie
Zhang, Gang-Ling
Application of triple evaluation method in predicting the efficacy of neoadjuvant therapy for breast cancer
title Application of triple evaluation method in predicting the efficacy of neoadjuvant therapy for breast cancer
title_full Application of triple evaluation method in predicting the efficacy of neoadjuvant therapy for breast cancer
title_fullStr Application of triple evaluation method in predicting the efficacy of neoadjuvant therapy for breast cancer
title_full_unstemmed Application of triple evaluation method in predicting the efficacy of neoadjuvant therapy for breast cancer
title_short Application of triple evaluation method in predicting the efficacy of neoadjuvant therapy for breast cancer
title_sort application of triple evaluation method in predicting the efficacy of neoadjuvant therapy for breast cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052864/
https://www.ncbi.nlm.nih.gov/pubmed/36978164
http://dx.doi.org/10.1186/s12957-023-02998-8
work_keys_str_mv AT hanxu applicationoftripleevaluationmethodinpredictingtheefficacyofneoadjuvanttherapyforbreastcancer
AT lihui applicationoftripleevaluationmethodinpredictingtheefficacyofneoadjuvanttherapyforbreastcancer
AT dongshasha applicationoftripleevaluationmethodinpredictingtheefficacyofneoadjuvanttherapyforbreastcancer
AT zhoushuiying applicationoftripleevaluationmethodinpredictingtheefficacyofneoadjuvanttherapyforbreastcancer
AT wangcaihong applicationoftripleevaluationmethodinpredictingtheefficacyofneoadjuvanttherapyforbreastcancer
AT guolin applicationoftripleevaluationmethodinpredictingtheefficacyofneoadjuvanttherapyforbreastcancer
AT yangjie applicationoftripleevaluationmethodinpredictingtheefficacyofneoadjuvanttherapyforbreastcancer
AT zhanggangling applicationoftripleevaluationmethodinpredictingtheefficacyofneoadjuvanttherapyforbreastcancer